| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Andrew Lo is Director at ABCL and has filed Form 4s across 3 companies. Andrew Lo's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.3M at current prices.
Historically, Andrew Lo's trades have earned a below-average insider score of 29/100 across 6 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -45.4%.
The biggest single holding is ROIV (~$1.9M) as Director.
Andrew Lo has 17 Form 4 filings on record from October 2017 to June 2026, across 4 companies: Director at BridgeBio Pharma (BBIO), 2020–2026; Director at AbCellera Biologics (ABCL), 2021–2025; Director at Roivant Sciences (ROIV), 2022, and 1 more.
The 24 reported transactions were 11 option or other derivative awards, 5 open-market sales, 5 open-market purchases and 3 stock awards.
Counted by filing, the open-market trades come to 2 purchases worth about $1.3M and 2 sales worth about $10.2M.
The largest open-market purchase was 86,938 shares of ABCL at an average $14.02 on December 3, 2021, about $1.2M. Twelve months later ABCL was down 9%.
The largest open-market sale was 95,599 shares of BBIO at an average $66.11 on November 18, 2025, about $6.3M.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | BBIO Bridgebio Pharma, Inc. | Director | Sell | 95,599 | $66.11 | $6,319,662.43 | -65.4% | +15.6% | - | |
| May 2, 2025 | BBIO Bridgebio Pharma, Inc. | Director | Sell | 100,000 | $38.50 | $3,849,900.00 | -48.6% | +22.6% | +77.8% | |
| Dec 30, 2021 | BBIO Bridgebio Pharma, Inc. | Director | Buy | 7,500 | $13.18 | $98,850.00 | +18.5% | -28.7% | -47.6% | |
| Dec 3, 2021 | ABCL Abcellera Biologics Inc. | Director | Buy | 86,938 | $14.02 | $1,218,870.76 | New | -35.5% | -9.3% |